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Historical background
According to a centuries-old European legend, 
children that tasted salty when kissed on the 
forehead were considered “enchanted” or “be-
witched” and would soon die. The first references 
to possible carriers of the disease appeared in the 
literature in the 16th century, as autopsy reports. 
The first records of an autopsy performed on a 
“cursed” 11-year-old girl who presumably died 
of cystic fibrosis was performed in 1595 by Pi-
eter Pauw, professor of Botany and Anatomy in 
Leiden, Netherlands, and included the first medi-
cal description of the related pancreatic lesions 1.
In 1606, Alonso y de los Ruyzes de Fonteca, 
professor of medicine in Henares, Spain, reported 
that one’s fingers tasted salty after rubbing the fore-
head of these supposedly bewitched children 1.
Nearly three centuries later, in 1905, Land-
steiner described meconium ileus, relating it to 
exocrine pancreatic insufficiency. Three decades 
later, Fanconi (1936) referred to the disease as 
cystic fibromatosis with bronchiectases and 
recognized it as a disease entity independent of 
celiac disease 1. At the same time, Dorothy An-
dersen, in 1938, described the disease in min-
ute detail, with its clinical, anatomopathological, 
and epidemiological characteristics, referring to 
it as “cystic fibrosis of the pancreas” 1.
In mid-1945, Farber believed that the cause 
of the disease was a generalized “state of thick-
ening of secretions”, thus coining the term mu-
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Abstract
The clinical and diagnostic aspects of cystic fibro-
sis have been extensively reviewed, with an em-
phasis on neonatal screening. This systematic lit-
erature review involved a search for relevant con-
tributions in the PubMed and SciELO databases. 
The first references to cystic fibrosis date to the 
Middle Ages. Cystic fibrosis is the most frequent 
autosomal recessive hereditary disease among 
Caucasians (1:2,000 to 3,500). More than 1,000 
mutations lead to the disease, the most common 
being ΔF508, with 70% prevalence among Cana-
dian, Northern European, and American Cauca-
sians and 23 to 55% prevalence among Brazil-
ians. The basic defect is in chloride ion secretion. 
Cystic fibrosis screening has long been contro-
versial, and after almost three decades, there are 
few nationwide programs (most are regional or 
local). However, the U.S. Centers for Disease Con-
trol and Prevention (CDC) has concluded that 
screening for cystic fibrosis is justified. The lack of 
a specific screening test and the ethnic heteroge-
neity of the Brazilian population pose challenges 
for neonatal screening.
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coviscidosis 2. Andersen and Hodges showed 
for the first time in 1946 that the disease had a 
genetic origin and resulted from an autosomal 
recessive mutation 1.
The year 1948 witnessed a strong heat wave 
in New York, and a high incidence of “prostra-
tion” was observed in patients treated at Colum-
bia Hospital. Based on careful observation by a 
young pediatrician, Paul di Sant’Agnese, children 
with prostration presented a diagnosis consis-
tent with cystic fibrosis. He further observed that 
these children had abnormal sweat, with high 
concentrations of sodium and chloride 3.
The sweat chloride test was standardized by 
Gibson & Cooke 4 in 1959 and is still considered 
the gold standard for diagnosing the disease.
In 1979, Crossley 5 demonstrated the in-
crease in plasma trypsinogen (IRT, immunoreac-
tive trypsin), thus providing a practical method 
that is still used for neonatal screening of cystic 
fibrosis.
In the early 1980s, Paul Quinton 6 and team 
began to unveil the basic defect in chloride ion 
secretion. Soon afterwards, researchers led by 
Francis Collins at the University of Michigan and 
Lap-Chee Tsui and Jack Riordan at the Hospital 
for Sick Children in Toronto located the gene for 
cystic fibrosis in the long arm of chromosome 7, 
which was cloned and sequenced 7,8,9. This dis-
covery allowed more accurate diagnosis of the 
disease and better understanding of the clinical 
disorders it causes and the impact of the defi-
ciency on its protein product, the cystic fibrosis 
transmembrane conductance regulator (CFTR).
Incidence
Cystic fibrosis incidence varies according to 
ethnic group, ranging from one in 2,000 to one 
in 3,500 Caucasians born in Europe, the United 
States, and Canada, and with the lowest inci-
dence among Hispanics (1:8,400 births), African-
Americans (1:15,000 births), and the Asian popu-
lation of Hawaii (1:89,000 births) 10.
Population studies in Brazil in the States of 
Paraná, Santa Catarina, Minas Gerais, and São 
Paulo report incidence rates of 1:9,520, 1:8,779, 
1:9,115, and 1:8,403, respectively 11,12,13,14.
The natural history of the disease has under-
gone major changes over the years. The first clini-
cal descriptions considered it “fatal” in the first 
year of life. In the 1960s, mean survival was 10 
years, increasing to 16 and 18 years, respectively, 
in the 70s and 80s; mean survival for patients fol-
lowed by specialized reference centers is now 30 
years, with many patients reaching 40 years of 
age 2.
The genetics of cystic fibrosis and the 
role of CFTR
Cystic fibrosis is an autosomal recessive heredi-
tary disease associated with a gene located in the 
long arm of chromosome 7, locus q31. The gene 
consists of 250 Kb, presents 27 coding sequences 
(exons), and transcribes a long ribonucleic acid 
(mRNA) with 6.5 Kb and an ion transmembrane 
transport regulatory protein, or chloride channel 
regulator known as the cystic fibrosis transmem-
brane conductance regulator (CFTR) 15.
Consistent with the characteristics of this 
gene family, the CFTR structure is comprised 
of five domains: two membrane-spanning do-
mains (MSDs), two nucleotide-binding domains 
(NBD1 and NBD2), and a regulatory domain (RD) 
(Figure 1) 16.
Figure 1



















The NBDs and RD are situated in the cyto-
plasm, while the MSDs form the main pore of 
the chloride channel. Both the RD and NBDs are 
involved in regulating the channel activity. The 
first stage consists of phosphorylation of the RD 
by a cAMP-dependent protein kinase. The NBDs 
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then bind and hydrolyze the ATP, providing en-
ergy that enables the channel to open and close. 
The absence of phosphate in the RD makes the 
channel impermeable to chloride ions.
The protein is made in the nucleus and un-
dergoes a complex process before locating in 
the cell membrane. This process includes two 
glycosylation stages, in the endoplasmic reticu-
lum and Golgi complex. This protein consists of 
1,480 amino acids and has a molecular weight of 
168,173 Da and functions as a cAMP-regulated 
chloride channel.
The protein, besides its principal function in 
chloride conductance, plays other roles, includ-
ing participation in sodium absorption. In the 
lungs, hydration of mucus is maintained by chlo-
ride secretion and sodium absorption.
Homozygous mutations in the cystic fibrosis 
gene result in absence of activity or partial func-
tioning of the CFTR and reduction in chloride ex-
cretion through the luminal epithelial surface. To 
maintain ionic neutrality, there is a compensa-
tory inflow of sodium and water, leading to dehy-
dration of the cell surface, with the formation of 
thickened mucus, characteristic of the disease 17.
Different forms of pathogenesis resulting from 
these alterations are present in the wide range 
of affected organs, including the pancreas, sweat 
glands, and respiratory, digestive, and reproduc-
tive tracts.
Currently, more than 1,000 mutations asso-
ciated with the disease have been described 16.
These mutations are distributed in 6 classes, 
having as their basis the mechanisms that de-
termine development of the disease: (a) class I 
causes a disorder in CFTR mRNA production and 
consequently a defect in the protein transcrip-
tion; (b) class II results from a processing defect: 
the protein is synthesized, but the post-transla-
tion modifications do not occur properly, and 
there is no glycosylation of the protein, which 
is retained in the endoplasmic reticulum and 
degraded before reaching the membrane; (c) 
class III is associated with a defect in regulation 
of the protein, which is located correctly in the 
cell membrane, but does not respond to cAMP 
agonist stimuli in the RD, essential for opening 
of the chloride channel; (d) class IV involves a 
reduction in chloride conductance, whereby the 
chloride ions fail to move effectively through 
the channel, leading to a conductance defect; 
(e) class V results in “splicing” abnormalities in 
the CFTR (removal of non-coding sequences, 
introns, from the primary RNA transcript, by 
an mRNA processing enzyme complex), with a 
partial reduction in the number of functioning 
chloride channels and reduced amount of func-
tional CFTR protein; and (f ) class VI, resulting 
from alterations in cell-surface CFTR stability 
(Figure 2) 10,16,18.
Figure 2
Classifi cation of the cystic fi brosis transmembrane conductance 
receptor (CFTR) mutations.
Mutations I, II, and III are associated with the 
more severe clinical forms, resulting in complete 
loss of chloride channel function, while muta-
tions IV and V produce milder clinical manifes-
tations, associated with altered conductance or 
reduction in the synthesis of normal CFTR 19.
The most commonly described mutation in 
the United States, called ΔF508, is characterized 
as a class II defect 18. CFTR with this mutation 
presents a deletion of three base pairs, involving 
the loss of an amino acid, phenylalanine, at posi-
tion 508 (exon 10). Thus, when the protein reach-
es the endoplasmic reticulum, the cell’s qual-
ity control mechanism recognizes the protein as 
“misfolded” (altered spatial conformation) and 
degrades it soon after synthesis, before reaching 
the cell surface 16.
The ΔF508 mutation is found in some 70% 
of Canadian, American, and Northern European 
Caucasian patients, decreasing in frequency in 
Modifi ed from Rowe et al. 16.
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Central and Southern Europe 20. In Brazil, the fre-
quency of this mutation, analyzed in the alleles of 
affected patients, varies from region to region: 49% 
in Rio Grande do Sul 21, 55% in Santa Catarina 22, 
31.7 to 52% in São Paulo 23,24,25, 39% in Paraná 25, 
32.6% in Minas Gerais 13, 22.7% in Pará 26,
and 30.68% in the State of Rio de Janeiro 27.
A recent study 22 analyzed the frequency of this 
mutation in European descendents in five Brazil-
ian States (Minas Gerais, São Paulo, Paraná, Santa 
Catarina, and Rio Grande do Sul) and observed 
that approximately 48% of the alleles in CF pa-
tients carried the ΔF508 mutation and estimated 
the prevalence of the disease at 1:7,576 live births 
in European-descendant Brazilians. Due to the 
country’s extensive miscegenation, the study al-
so showed a large regional variation, estimating 
the mutation’s prevalence at 1:32,258 in children 
born in the State of São Paulo and 1:1,587 in Rio 
Grande do Sul.
The other mutations are rare (< 1%), with 10 
of them showing a frequency of 2% to 10% in vari-
ous populations, for example G542X (class I mu-
tation), G551D (class III mutation), and R117H 
and A455E (class IV) 16. In Brazil, the G542X mu-
tation is found more frequently in the States of 
São Paulo and Minas Gerais (19.6% and 13.8% re-
spectively) than in the States of Rio de Janeiro, Rio 
Grande do Sul, Santa Catarina, and Paraná (2.1, 
4.9, 6.2, and 8.7%, respectively) 28,29. In the States 
of Santa Catarina and Paraná, other rare muta-
tions have been reported, like N1303K (4.5%), 
G85E, R334W, and R1162X (3.6%), 2183AA>G 
and W1282X (2.7%), and R553X (1.8%) 30. In the 
State of Rio de Janeiro, among the rare mutations, 
3120+1GA was found in 3.7% of the alleles 29. 
Cabello et al. 31 explain the higher frequency of 
this mutation, 3120+1GA, as the result of the 
population’s ethnic composition in the State of 
Rio de Janeiro, with a higher proportion of Afri-
can-descendants. Meanwhile, the G551D muta-
tion, occurring in less than 1% in the State of Rio 
de Janeiro, was found in 3% of the alleles studied 
in the State of Pará 26.
Clinical manifestations of cystic fibrosis
Cystic fibrosis is characterized by a wide hetero-
geneity of manifestations, but the classical triad 
consists of chronic lung disease, pancreatic in-
sufficiency, and high sodium chloride levels in 
sweat.
The lung is affected by chronic infections, 
accounting for the disease’s high morbidity and 
early mortality.
The chloride transport defect leads to in-
creased sodium absorption, decreased water 
secretion, and greater reabsorption of pericili-
ary fluid. The result is decreased fluid volume on 
the airways surfaces, with the formation of thick, 
viscous mucus, ineffective for mucociliary trans-
port, leading to secondary infection and inflam-
mation 10,22.
Alterations in airways surface liquid and mu-
cociliary clearance mean that host chemotaxins 
(interleukin-8) and bacteria in the airways lead to 
intense migration of neutrophils in the lungs. The 
presence of abundant neutrophils in the airways 
causes the release of elastase and large amounts 
of DNA, resulting from their breakdown, making 
the mucus even more viscous and leading to the 
appearance of proinflammatory substances 32.
In cystic fibrosis, inflammation occurs early, 
precedes infection, and predisposes to coloniza-
tion and infection of the airways, creating a vi-
cious cycle that is a major cause of lung function 
decline in these patients 33.
Colonization of the airways by opportunis-
tic bacteria causes irreversible tissue damage in 
CF patients. The most frequently involved bac-
teria are: Pseudomonas aeruginosa, Burkholderia 
cepacia, Staphylococcus aureus, and Haemophi-
lus influenzae, which adhere readily to airways 
secretions and are not eliminated effectively 19. 
Some bacteria adapt to the medium, making 
it difficult to eradicate them. One example is P. 
aeruginosa, which adapts to the pulmonary mi-
cro-environment through the formation of mac-
rocolonies (or biofilms) and the production of 
a capsular polysaccharide that inhibits penetra-
tion by antimicrobial agents, thereby giving the 
lung a mucoid appearance 16.
Pancreatic insufficiency is already present at 
birth in some 75% of individuals with CF, in 80 to 
85% by the end of the first year of life, and in some 
90% by adulthood 34. The pancreas displays a de-
crease in the formation of pancreatic juice and 
bicarbonate due to the non-functioning of the 
chloride channels in ductal epithelial cells; with-
out ductal fluid, there is no enzyme transport. 
Due to obstruction of the pancreatic canaliculi, 
the enzymes secreted in the acini fail to reach the 
duodenum, leading to deficient digestion and 
malabsorption of macro and micronutrients 34. 
Voluminous, fatty, pale feces with a characteristic 
odor result from the deficient digestion, finally 
involving more or less severe protein-calorie 
malnutrition due to loss of nutrients through the 
feces. In addition, a process of pancreatic autodi-
gestion begins which can last for months or years; 
in some patients, the insulin-producing beta cells 
in the islets of Langerhans are also destroyed, 
leading to the emergence of diabetes mellitus 35.
The sweat glands of CF patients do not gen-
erally present obstruction or significant mor-
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phological alterations, but they do display ab-
normalities in sodium chloride homeostasis. In 
the sweat glands of normal individuals, the first 
secretion produced in the glandular annulus is 
modified as it crosses the duct, before emerging 
on the skin’s surface. Under normal conditions, 
sodium (followed by chloride ions) is rapidly 
reabsorbed from the ductal lumen, through the 
apical sodium channels and the CFTR. In CF 
patients, the lack of CFTR functioning restricts 
chloride reabsorption, thus limiting the amount 
of salt that can be reutilized. Since there is no 
other route for effective chloride reabsorption in 
the duct, sodium is also poorly absorbed, and the 
sweat emerging on the skin’s surface has a high 
salt content 16.
Men with cystic fibrosis are frequently sterile 
due to obstruction of the vas deferens 16. In the 
female reproductive tract, the gene’s expression 
varies in the cervical epithelium and Fallopian 
tubes and is high in the endometrium. Women 
with CF ovulate normally but experience diffi-
culty in conceiving due to thick cervical mucus, 
which acts as a barrier against sperm cells.
Neonatal screening for cystic fibrosis
The implementation of neonatal screening for 
cystic fibrosis involves great controversy, consid-
ering questions as to the benefits of early diag-
nosis of the disease, the various protocols for its 
detection, and the costs involved 36.
In 1979 in New Zealand, Crossley et al. 5 in-
troduced the testing of immunoreactive trypsin 
(IRT) for CF screening, developing a method that 
allowed measurement in dried blood and there-
fore universal screening for cystic fibrosis. This 
test is still the basis for CF screening protocols.
Trypsinogen is a precursor for pancreatic en-
zyme, the concentration of which is usually per-
sistently high in the blood of newborns with cys-
tic fibrosis, even in cases where there is still pan-
creatic sufficiency 37. This increase results from 
the pancreatic fibrosis displayed by the majority 
of individuals with CF even in the intrauterine 
period, leading to a reflux of pancreatic enzymes 
into the circulation and increased IRT levels.
Crossley et al. 5 used a radioimmunoassay 
with polyclonal antibodies to measure IRT on 
Guthrie cards. This method was later improved 
with the introduction of an enzymatic immuno-
assay with monoclonal antibodies and performed 
on ELISA plates, leading to increased sensitivity 
and shorter processing time 38.
Various screening protocols are based on the 
IRT test as a preliminary tool for CF screening. 
These protocols have advantages and disadvan-
tages. The choice depends on various factors, 
like cost, collection time, and the specific genetic 
background in each region to be screened 38. Al-
most universally, screening tests do not detect all 
affected children, and few cases will be detected 
clinically after a negative neonatal test.
Currently used protocols
• IRT/IRT
The protocol initially adopted for screening pro-
grams was the two-stage IRT. When the first IRT 
(IRT1) is high, it is necessary to draw a second 
blood sample for new IRT measurement (IRT2); if 
the second test is also high, the sweat test is per-
formed for the definitive diagnosis. This protocol 
was initially adopted in various countries, in-
cluding Australia, Austria, Belgium, France, Italy, 
England, New Zealand, and the United States.
Travert analyzed the results for 2 million 
children screened by the IRT/IRT protocol in 15 
laboratories, with four different testing systems, 
three of which by radioimmunoassay. Of the 730 
children with cystic fibrosis, 6.4% were not diag-
nosed by the screening test. The positive predic-
tive value (PPV) varied from 3% to 10% for the 
first IRT test and was around 52% for the second 
test. There was large variability between labora-
tories, partially explained by the different anti-
bodies used at the time 38.
The test’s PPV and specificity depend on the 
cutoff point, and most programs adopt a cutoff 
that results in a 0.3-1.0% recall rate. The cutoff 
points can be fixed or vary between assays, using 
percentages 38.
Since IRT levels decrease over time, some 
screening programs adopt a lower cutoff, around 
50ng/ml, for the second IRT test 39.
With the IRT/IRT protocol, approximately 
one in 200 children requires a second IRT 38, 
causing great anxiety in the parents. According 
to the Wisconsin program in the United States, 
fetal distress accounts for 25% of the false-posi-
tive results 40. Other factors include intestinal 
atresia, congenital infections, and trisomies 13 
and 18 38,41.
Approximately 95% of children with cystic fi-
brosis are detected with this protocol, but with a 
high percentage of false-positive results.
• IRT/DNA
Identification of the CFTR gene in 1989 and of the 
most frequent mutation, D F508, in some po-
pulations allowed performing efficient neonatal 
screening with a single blood sample. IRT is mea-
sured in routine neonatal screening samples, and 
Rodrigues R et al.S480
Cad. Saúde Pública, Rio de Janeiro, 24 Sup 4:S475-S484, 2008
those with high levels are processed for the anal-
ysis of mutations, using DNA isolated from blood 
eluted from the same filter paper.
When two mutations are found, the diagnosis 
of cystic fibrosis is confirmed; when one muta-
tion is found the patient must undergo the sweat 
test, since the individual may merely be a carrier 
of one of the CF genes or may present cystic fi-
brosis if there is a second mutation that was not 
investigated by the genetic test used. When no 
mutation is detected, the probability of cystic fi-
brosis is low, with no need for the sweat test.
Using this strategy, a group of Australian re-
searchers 42 observed better specificity and PPV, 
fewer false-positives, and a 96% detection rate.
An analysis of nine years of experience in CF 
screening in Wisconsin also showed an improve-
ment in the screening results with the inclusion 
of this protocol. Initially, with the IRT/IRT pro-
tocol, the sensitivity, specificity, and PPV were 
87%, 99.9%, and 12.5%, respectively. With the 
new method, the sensitivity increased to 94%, 
besides allowing earlier identification of affected 
children and fewer false-positives, besides not 
requiring a second IRT test and allowing the 
benefit of genetic counseling. In 2002, neonatal 
screening for cystic fibrosis in Wisconsin began 
analyzing 25 types of mutations, increasing the 
diagnostic sensitivity to 99% and the diagnosis of 
affected individuals from 41% (investigating one 
mutation) to 64% 43.
This program’s costs were also evaluated and 
proved similar to those of other well-established 
disorders, like phenylketonuria (US$ 3.64) and 
hypothyroidism (US$ 4.42), while the estimated 
cost for molecular analysis was approximately 
US$ 4.00 per newborn 43.
• IRT/DNA/IRT
This protocol combined a first IRT test with DNA 
analysis for the ΔF508 mutation and a second 
sample for IRT when the child had a mutant allele. 
Pollitt et al. 44, using this methodology, observed 
a reduction of 92% in the number of recalls for 
a second IRT test, as compared to the IRT/IRT 




Pancreatitis-associated protein (PAP) is elevated 
in the blood of children with cystic fibrosis 44. 
Sarles et al. 45 studied the combined use of mea-
suring PAP and IRT. In the limited number of chil-
dren they tested, they concluded that this proto-
col has good sensitivity and high specificity and 
can preclude performing the genetic test, which 
requires informed consent according to the legis-
lation in many countries.
• Meconium lactase
Italian researchers have studied the measure-
ment of meconium lactase as an additional test 
associated with IRT and/or DNA analysis. Based 
on their studies, they postulated that performing 
IRT at birth, associated with the lactase test and 
analysis of three mutations, led to higher sensi-
tivity and a considerable increase in specificity, 
principally in genetically diverse populations 46. 
This protocol requires two different samples and 
is not currently applied elsewhere.
Cystic fibrosis screening around the world
There are few nationwide neonatal screening 
programs for cystic fibrosis implemented around 
the world. Most of the existing programs are re-
gional.
According to an evaluation of the situation 
with CF screening in various countries by South-
ern & Littlewood 47 in 2003, Canada, Spain, Es-
tonia, Finland, Greece, Israel, Ireland, Jordan, 
Mexico, Netherlands, Norway, Portugal, Slovak 
Republic, Sweden, and Switzerland did not have 
national screening programs for the disease. 
In other countries, pilot studies had been per-
formed, but the decision was made not to imple-
ment the program. The latter included Denmark, 
which opted for pre-conception screening, and 
Germany and the Netherlands, which initially 
used the meconium test, with high false-positive 
and false-negative rates, resulting in the non-in-
troduction of a national program. Meanwhile, 
other countries like Australia, Austria, Belgium, 
France, Italy, New Zealand, and Poland launched 
their programs in the years 1981, 1988, 1988, 
1988, 1973, 1981, and 1999, respectively.
In 2003, in England, six centers performed 
screening, with coverage of 22% of newborns, 
and the national program was implemented in 
2004. In the United States at the time, six States 
(Colorado, Massachusetts, New Jersey, New York, 
Wyoming, and Wisconsin) had implemented 
their own programs, and three (Connecticut, 
Montana, and Pennsylvania) did partial screen-
ing 47.
A recent publication by the European Cystic 
Fibrosis Foundation 39 reported on the current 
situation with CF screening in Europe. Twenty-
six centers participated in this evaluation: seven 
from England, 12 from Italy, three from Spain, 
and one each from Austria, France, Poland, 
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and Czech Republic, while in France and Aus-
tria neonatal screening is centralized in a single 
laboratory. These services have been working 
with CF neonatal screening for an average of ten 
years (varying from nine months to 31 years), 
screening 1,600,000 children/year and detecting 
some 400 cases/year. Median age at diagnosis is 
reported at 37 days (32-50). This was the first de-
tailed report on CF screening in Europe, and the 
results showed heterogeneous protocols, varying 
from the sweat test after the first IRT to those in-
volving IRT1/IRT2/DNA, IRT1/DNA/IRT2, IRT1/
protein in meconium/IRT2, IRT1/sweat chloride 
test. Nineteen programs use DNA testing after 
the first IRT. The median number of mutations 
analyzed is 31.
In the United States, 34 of the 50 States cur-
rently perform screening for cystic fibrosis 
(http://genes-r-us.uthscsa.edu/, accessed on 
03/Jan/2008).
In Brazil, CF neonatal screening was the ob-
ject of a ruling by the Ministry of Health in 2001. 
The screening test is the IRT, with investigation 
of the D F508 mutation being available for di-
agnostic confirmation. The public program is 
implemented in routine neonatal screening in 
the States of Santa Catarina, Paraná, and Minas 
Gerais. In other States it has been performed in 
some private laboratories.
In Paraná, CF screening began in 2001, using 
the IRT/IRT protocol and with the sweat chloride 
test for diagnostic confirmation. The first report 
on the experience with screening in Paraná in-
volved 456,982 newborns from September 2001 
to April 2004 and found 4,028 (0.9%) children 
with the first IRT higher than 70ng/ml. Of these, 
3,815 (94.7%) appeared for the second IRT, which 
was altered in 478 (12.8%), while 48 (0.01%) had 
the diagnosis confirmed by the sweat chloride 
test (cutoff of 50mMol/l). These results showed 
a high false-positive rate in the first IRT, and the 
incidence of cystic fibrosis was 1:9,520 newborns 
in the State 11.
In the State of Santa Catarina, CF neonatal 
screening was evaluated for the period from Oc-
tober 2000 to December 2005, using as the pro-
tocol the IRT test from the fourth to seventh day 
of life, with a cutoff of 70ng/ml, with the second 
test performed up to 30 days of life and three 
samples of sweat chloride for the definitive diag-
nosis. During this period 386,183 children were 
screened; of these, 3,902 (1%) had an altered first 
IRT and 181 (0.05%) an altered second IRT. Forty-
four cases of cystic fibrosis were diagnosed, for 
an incidence of 1:8,776. All the children with CF 
were white, 11 homozygous and 14 heterozygous 
for the ΔF508 mutation. Mean age at diagnosis 
was 64 days 12.
In Minas Gerais, CF screening began in July 
2003. From the beginning of the program until 
April 2005, 455,755 newborns were screened, 53 
of whom were identified with cystic fibrosis (in-
cidence of 1:9,115). Mean age at diagnosis was 
51.4 days 13.
In the State of São Paulo, a pilot study for 
implementation of CF screening tested 33,600 
infants from the North, Northeast, and West of 
the State and showed a similar incidence to that 
of other States of Brazil, estimated at 1:8,403. 
Mean age at diagnosis in this study was 69 days, 
and of the four children diagnosed through this 
screening, three already presented overt symp-
toms of the disease when the diagnosis was con-
firmed 14.
The benefits of early treatment related to im-
provement in the child’s nutritional status and 
growth are unquestionable 48. However, this evi-
dence is less clear when analyzing the evolution 
of the pulmonary disease and long-term survival 
37,49,50. However, detecting the disease in its as-
ymptomatic stage can provide a valuable oppor-
tunity to collect epidemiological data and obtain 
better understanding of the natural history of the 
disease 51. In addition, in relation to P. aeruginosa 
infection (the principal risk factor for morbidity 
and mortality), early diagnosis can serve to test 
the efficacy of preventive therapeutic strategies 
and could help improve prognosis 51,52.
However, although CF screening has been 
available for nearly three decades, there are few 
nationwide programs, with the majority imple-
mented at the regional or local level. The reasons 
for this include uncertainties as to the long-term 
benefits and the lack of a definitive screening test 
50,53,54. Since cloning of the CF gene in 1989 7,8,9 
and the availability of molecular testing for diag-
nosing the disease, other questions have arisen: 
(i) Are the benefits of early diagnosis for the child’s 
growth and nutrition sufficient to justify screen-
ing? (ii) Would detecting carriers of the mutation, 
when used for diagnosis, produce some harm 
for these individuals? (iii) Approximately 5% of 
the children identified through screening pres-
ent a borderline sweat test (concentrations of 30-
40mmol/L) and more “benign” mutations. How 
many of these individuals will have health prob-
lems and require treatment for the disease?
However, analyzing all these issues, in 2003 
the U.S. Centers for Disease Control and Preven-
tion (CDC) published guidelines for cystic fibro-
sis screening 55. The report concluded that CF 
screening is justified on grounds of evidence of 
moderate benefit and low risk of harm, despite 
acknowledging that the individual States should 
assess their available resources and the concur-
rent public health priorities.
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Resumo
Aspectos clínicos e diagnósticos da fibrose cística são 
revistos de modo abrangente, com ênfase na triagem 
neonatal. Esta revisão sistematizada da literatura en-
volveu busca de contribuições relevantes nos bancos de 
dados PubMed e SciELO. Referências sobre fibrose cís-
tica existem desde a Idade Média. É a doença heredi-
tária autossômica recessiva mais freqüente em cauca-
sianos (1:2.000 a 3.500). Mais de mil mutações levam 
à doença, a mais comum: ΔF508 (prevalência: 70% em 
caucasianos canadenses, americanos e norte-europeus; 
de 23 a 55% em brasileiros). O defeito básico ocorre na 
secreção do íon cloro. Sua triagem é assunto polêmico 
e apesar de estar disponível há quase três décadas, por 
meio de diferentes protocolos, poucos programas de 
abrangência nacional existem. Entretanto, o Centers 
for Disease Control and Prevention, dos Estados Uni-
dos, afirma que o rastreamento neonatal para fibrose 
cística é justificado. A falta de um teste específico e a 
heterogeneidade étnica da população brasileira difi-
cultam sua triagem neonatal.
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